New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePGPIPN vs P21

PGPIPN vs P21

Side-by-side comparison of key properties, dosing, and research.

Immune Support
PGPIPN
Cognitive EnhancementAnti-Aging & Longevity
P21
Summary
PGPIPN is a bioactive hexapeptide (Pro-Gly-Pro-Ile-Pro-Asn) derived from beta-casein during enzymatic digestion. It exhibits anti-inflammatory properties via opioid receptor modulation and cytokine suppression, making it relevant for gut health, systemic inflammation, and as a component of casein-derived functional foods.
P21 is a synthetic peptide derived from CNTF (ciliary neurotrophic factor) that promotes hippocampal neurogenesis, enhances memory and spatial learning, and may reduce amyloid-beta pathology. It is used as a neurogenic and cognitive enhancer with potential anti-Alzheimer's applications.
Half-Life
Estimated 30-120 minutes (peptide degradation)
Not well characterized; likely short, but neurogenic effects persist long after administration
Admin Route
Oral, Subcutaneous (research)
SubQ, Intranasal
Research
Typical Dose
200-500 mg per day
100–500 mcg
Frequency
Once or twice daily
Once daily
Key Benefits
  • Anti-inflammatory effects via cytokine suppression
  • Gut mucosal protection and intestinal barrier support
  • Opioid receptor modulation for gut motility regulation
  • Potential analgesic activity via central and peripheral opioid pathways
  • Explored for inflammatory bowel conditions and gut dysbiosis
  • Natural origin (food-derived) with favorable safety profile
  • Promotes hippocampal neurogenesis
  • Enhances spatial memory and learning
  • Increases BDNF expression
  • Reduces amyloid-beta plaque formation (animal models)
  • Anti-tau pathology potential
  • Cognitive enhancement without stimulant effects
  • Potential therapeutic for Alzheimer's and cognitive aging
Side Effects
  • Generally very well-tolerated given food-derived origin
  • Theoretical opioid-mediated constipation at high doses
  • Rare milk protein allergy in casein-sensitive individuals
  • Generally well tolerated in animal studies
  • Limited human clinical data
  • Injection site reactions
  • Potential mild fatigue at initiation
Stacks With